GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » La Jolla Pharmaceutical Co (NAS:LJPC) » Definitions » Current Ratio

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Current Ratio : 4.02 (As of Jun. 2022)


View and export this data going back to 1994. Start your Free Trial

What is La Jolla Pharmaceutical Co Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. La Jolla Pharmaceutical Co's current ratio for the quarter that ended in Jun. 2022 was 4.02.

La Jolla Pharmaceutical Co has a current ratio of 4.02. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for La Jolla Pharmaceutical Co's Current Ratio or its related term are showing as below:

LJPC' s Current Ratio Range Over the Past 10 Years
Min: 0.26   Med: 7.06   Max: 33.64
Current: 4.02

During the past 13 years, La Jolla Pharmaceutical Co's highest Current Ratio was 33.64. The lowest was 0.26. And the median was 7.06.

LJPC's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.77 vs LJPC: 4.02

La Jolla Pharmaceutical Co Current Ratio Historical Data

The historical data trend for La Jolla Pharmaceutical Co's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

La Jolla Pharmaceutical Co Current Ratio Chart

La Jolla Pharmaceutical Co Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.07 6.98 3.96 2.95 3.82

La Jolla Pharmaceutical Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.05 4.12 3.82 3.92 4.02

Competitive Comparison of La Jolla Pharmaceutical Co's Current Ratio

For the Biotechnology subindustry, La Jolla Pharmaceutical Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


La Jolla Pharmaceutical Co's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, La Jolla Pharmaceutical Co's Current Ratio distribution charts can be found below:

* The bar in red indicates where La Jolla Pharmaceutical Co's Current Ratio falls into.



La Jolla Pharmaceutical Co Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

La Jolla Pharmaceutical Co's Current Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Current Ratio (A: Dec. 2021 )=Total Current Assets (A: Dec. 2021 )/Total Current Liabilities (A: Dec. 2021 )
=67.315/17.635
=3.82

La Jolla Pharmaceutical Co's Current Ratio for the quarter that ended in Jun. 2022 is calculated as

Current Ratio (Q: Jun. 2022 )=Total Current Assets (Q: Jun. 2022 )/Total Current Liabilities (Q: Jun. 2022 )
=66.361/16.493
=4.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


La Jolla Pharmaceutical Co  (NAS:LJPC) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


La Jolla Pharmaceutical Co Current Ratio Related Terms

Thank you for viewing the detailed overview of La Jolla Pharmaceutical Co's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
201 Jones Road, Suite 400, Waltham, MA, USA, 02451
La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
Executives
Larry G. Edwards director, officer: Chief Executive Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Michael S Hearne officer: Chief Financial Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Robert Rosen director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Kevin C Tang director, 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Darryl Wellinghoff officer: Chief Commercial Officer 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Lakhmir S Chawla officer: Chief Medical Officer 1960 KIRBY ROAD, MCLEAN VA 22101
Jennifer Carver officer: Sr. Vice President, Operations 725 NEWPORT STREET, DENVER CO 80220
James Rolke officer: Chief Scientific Officer 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
George F Tidmarsh director, officer: President, CEO & Secretary

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Headlines

From GuruFocus

Innoviva to Acquire La Jolla Pharmaceutical Company

By Business Wire Business Wire 07-11-2022